An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Zontivity

Chemical Namevorapaxar
Dosage FormTablet (oral; 2.08mg)
Drug ClassReceptor antagonists
SystemCardiovascular
CompanyMerck & Co.
Approval Year2014

Indication

  • For the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD).
Last updated on 4/20/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Zontivity (vorapaxar) Prescribing Information2014MSD International GmbH (Singapore Branch), Singapore
Document TitleYearSource
Antithrombotic treatments in patients with chronic coronary artery disease or peripheral artery disease: A systematic review of randomised controlled trials.2020Cardiovascular Therapeutics
Safety and efficacy of vorapaxar in secondary prevention of atherosclerotic disease: A meta-analysis of randomized control trials.2017International Journal of Cardiology